Activity of linezolid against Gram-positive cocci isolated in French hospitals as determined by three in-vitro susceptibility testing methods

Clinical Microbiology and Infection

Volumn 10, Issue 3, 2004, Pages 242-246

  Muller Serieys, Claudette ^a   Drugeon, H B ^b   Etienne, J ^c   Lascols, C ^d   Leclerq, R ^e   Nguyen, J ^f   Soussy, C J ^d  

^a BICHAT HOSPITAL   (France)

^b CHU de Nantes   (France)

^c EDOUARD HERRIOT HOSPITAL   (France)

^d HENRI MONDOR HOSPITAL   (France)

^e CHU CÔTE DE NACRE   (France)

^f PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

Author keywords

Antibacterial activity; Gram positive cocci; Linezolid; Testing methods

Indexed keywords

AGAR; AMINOGLYCOSIDE; BETA LACTAM ANTIBIOTIC; COAGULASE; ERYTHROMYCIN; GENTAMICIN; GLYCOPEPTIDE; LINCOMYCIN; LINEZOLID; MACROLIDE; METICILLIN; PEFLOXACIN; PENICILLIN G; PRISTINAMYCIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; TEICOPLANIN; VANCOMYCIN;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL STRAIN; BACTERIUM ISOLATE; BETA HEMOLYTIC STREPTOCOCCUS; COAGULASE NEGATIVE STAPHYLOCOCCUS; CONTROLLED STUDY; DILUTION; ENTEROCOCCUS; ENTEROCOCCUS FAECALIS; ENTEROCOCCUS FAECIUM; FRANCE; GRAM POSITIVE COCCI; IN VITRO STUDY; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PENICILLIN RESISTANCE; PRIORITY JOURNAL; STAPHYLOCOCCUS; STREPTOCOCCUS PNEUMONIAE; UNIVERSITY HOSPITAL;

ENTEROCOCCUS; ENTEROCOCCUS FAECALIS; ENTEROCOCCUS FAECIUM; POSIBACTERIA; STAPHYLOCOCCUS; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS; STREPTOCOCCUS PNEUMONIAE;

EID: 1642342273     PISSN: 1198743X     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1198-743X.2004.00751.x     Document Type: Article

References (20)

1. Swaney SM, Aoki H, Ganoza MC, Shinabarger DL. The oxazolidinone linezolid inhibits initiation of protein synthesis in bacteria. Antimicrob Agents Chemother 1998; 42: 3251-3255.
2. Shinabarger D. Mechanism of action of oxazolidinone antibacterial agents. Expert Opin Invesigt Drugs 1999; 8: 1195-1202.
3. Fines M, Leclercq R. Activity of linezolid against Gram-positive cocci possessing genes conferring resistance to protein synthesis inhibitors. J Antimicrob Chemother 2000; 45: 797-802.
4. Ford CW, Hamel JC, Stapert D et al. Oxazolidinones: New antibacterial agents. Trends Microbiol 1997; 5: 196-200.
5. Struwig MC, Botha PL, Chalkley LJ. In vitro activities of 15 antimicrobial agents against clinical isolates of South African enterococci. Antimicrob Agents Chemother 1998; 42: 2752-2755.
6. Chien JW, Kucia ML, Salata RA. Use of linezolid, an oxazolidinone, in the treatment of multidrug-resistant gram-positive bacterial infections. Clin Infect Dis 2000; 30: 146-151.
7. Clemett D, Markham A. Linezolid. Drugs 2000; 59: 815-827.
8. Zurenko GE, Yagi BH, Schaadt RD et al. In vitro activities of U-100592 and U-100766, novel oxazolidinone antibacterial agents. Antimicrob Agents Chemother 1996; 40: 839-845.
9. Goldstein EJ, Citron DM, Merriam CV. Linezolid activity compared to those of selected macrolides and other agents against aerobic and anaerobic pathogens isolated from soft tissue bite infections in humans. Antimicrob Agents Chemother 1999; 43: 1469-1474.
10. Edlund C, Oh H, Nord CE. In vitro activity of linezolid and eperezolid against anaerobic bacteria. Clin Microbiol Infect 1999; 5: 51-53.
11. Comité de l'Antibiogramme. Communiqué 2002. Paris, France: Société Française de Microbiologie, 2002.
12. von Eiff C, Peters G. Comparative in-vitro activities of moxifloxacin, trovafloxacin, quinupristin/dalfopristin and linezolid against staphylococci. J Antimicrob Chemother 1999; 43: 569-573.
13. Ballow C, Jones R, Biedenbach D, Bolmstrom A. Multicentre evaluation of linezolid antimicrobial activity in Europe. Clin Microbiol Infect 2001; 7(suppl 1): 268.
14. Cuny C, Witte W. In vitro activity of linezolid against staphylococci. Clin Microbiol Infect 2000; 6: 331-333.
15. Rybak MJ, Hershberger E, Moldovan T, Grucz RG. In vitro activities of daptomycin, vancomycin, linezolid, and quinupristin-dalfopristin against staphylococci and enterococci, including vancomycin-intermediate and - resistant strains. Antimicrob Agents Chemother 2000; 44: 1062-1066.
16. Henwood CJ, Livermore DM, Johnson AP, James D, Warner M, Gardiner A. Susceptibility of gram-positive cocci from 25 UK hospitals to antimicrobial agents including linezolid. The Linezolid Study Group. J Antimicrob Chemother 2000; 46: 931-940.
17. Cercenado E, Garcia-Garrote F, Bouza E. In vitro activity of linezolid against multiply resistant Gram-positive clinical isolates. J Antimicrob Chemother 2001; 47: 77-81.
18. Wise R, Andrews JM, Boswell FJ, Ashby JP. The in-vitro activity of linezolid (U-100766) and tentative breakpoints. J Antimicrob Chemother 1998; 42: 721-728.
19. Betriu C, Redondo M, Palau ML et al. Comparative in vitro activities of linezolid, quinupristin-dalfopristin, moxifloxacin, and trovafloxacin against erythromycin-susceptible and -resistant streptococci. Antimicrob Agents Chemother 2000; 44: 1838-1841.
20. Johnson AP, Warner M, Livermore DM. Activity of linezolid against multi-resistant gram-positive bacteria from diverse hospitals in the United Kingdom. J Antimicrob Chemother 2000; 45: 225-230.